Cover Image
市場調查報告書

傷寒症:開發平台分析

Typhoid Fever - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 203746
出版日期 內容資訊 英文 55 Pages
訂單完成後即時交付
價格
Back to Top
傷寒症:開發平台分析 Typhoid Fever - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 55 Pages
簡介

傷寒症是造成腹瀉和皮疹的感染疾病。最常是由被稱為傷寒菌(S.typhi)的細菌引起。常見的症狀有腹部壓痛,興奮,發冷,譫妄症,幻覺,重度的疲勞·虛弱等。治療方法包含抗生素和支持療法。

本報告提供傷寒症的治療藥開發情形調查分析,提供您開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

傷寒症概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • Chongqing Zhifei Biological Products Co., Ltd.
  • GlaxoSmithKline Plc
  • Prokarium Limited
  • Protein Potential, LLC
  • Shantha Biotechnics Limited
  • USV Limited
  • Zydus Cadila Healthcare Limited

治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (typhoid fever + shigellosis) multivalent vaccine
  • Typhella
  • Typhetec
  • typhoid + paratyphoid (bivalent) vaccine
  • typhoid + paratyphoid vaccine
  • typhoid + pneumococcal vaccine
  • typhoid and paratyphoid fever vaccine
  • polysaccharide vaccine
  • typhoid vaccine
  • ViCRM-197

最新開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8239IDB

Summary

Global Markets Direct's, 'Typhoid Fever - Pipeline Review, H2 2016', provides an overview of the Typhoid Fever pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Typhoid Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Typhoid Fever and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Typhoid Fever
  • The report reviews pipeline therapeutics for Typhoid Fever by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Typhoid Fever therapeutics and enlists all their major and minor projects
  • The report assesses Typhoid Fever therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Typhoid Fever

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Typhoid Fever
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Typhoid Fever pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Typhoid Fever Overview
  • Therapeutics Development
    • Pipeline Products for Typhoid Fever - Overview
    • Pipeline Products for Typhoid Fever - Comparative Analysis
  • Typhoid Fever - Therapeutics under Development by Companies
  • Typhoid Fever - Therapeutics under Investigation by Universities/Institutes
  • Typhoid Fever - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Typhoid Fever - Products under Development by Companies
  • Typhoid Fever - Products under Investigation by Universities/Institutes
  • Typhoid Fever - Companies Involved in Therapeutics Development
    • GlaxoSmithKline Plc
    • Indian Immunologicals Limited
    • Nanotherapeutics, Inc.
    • Prokarium Limited
    • Protein Potential, LLC
    • Sanofi Pasteur SA
    • Shantha Biotechnics Limited
    • SK Chemicals Co., Ltd.
    • Zydus Cadila Healthcare Limited
  • Typhoid Fever - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (paratyphoid (bivalent) + typhoid) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (paratyphoid + typhoid) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (shigella + typhoid) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (Streptococcal pneumonia + typhoid) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Typhella - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Typhetec - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • typhoid vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • typhoid vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • typhoid vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • typhoid vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • typhoid Vi polysaccharide [strain S typhi Ty2] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ViCRM-197 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Typhoid Fever - Dormant Projects
  • Typhoid Fever - Discontinued Products
  • Typhoid Fever - Product Development Milestones
    • Featured News & Press Releases
      • Mar 11, 2013: Prokarium And University Of Birmingham Receive £0.4m Grant To Develop Next Generation Vaccines
      • Oct 05, 2012: Sanofi Pasteur Voluntarily Recalls Few Batches Of Typhoid Fever Vaccine
      • Jun 23, 2011: Sanofi Pasteur's Typhim Vi Receives Prequalification From World Health Organization
      • Jun 05, 2008: Emergent BioSolutions Initiates U.S. Phase II Trial of Oral Typhoid Vaccine Candidate
      • Jan 08, 2008: Emergent BioSolutions Announces Final Phase II Clinical Study Results for Typhoid Vaccine
      • Nov 21, 2005: Emergent Biosolutions Starts Clinical Study Of Single-Dose Oral Typhoid Vaccine
      • Aug 30, 2005: Emergent Biosolutions' Typhoid Vaccine Achieves Positive Results In Phase II Clinical Study
      • Nov 29, 1994: Food And Drug Administration Grants License For A New Typhoid Fever Vaccine
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Typhoid Fever, H2 2016
  • Number of Products under Development for Typhoid Fever - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Typhoid Fever - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Typhoid Fever - Pipeline by Indian Immunologicals Limited, H2 2016
  • Typhoid Fever - Pipeline by Nanotherapeutics, Inc., H2 2016
  • Typhoid Fever - Pipeline by Prokarium Limited, H2 2016
  • Typhoid Fever - Pipeline by Protein Potential, LLC, H2 2016
  • Typhoid Fever - Pipeline by Sanofi Pasteur SA, H2 2016
  • Typhoid Fever - Pipeline by Shantha Biotechnics Limited, H2 2016
  • Typhoid Fever - Pipeline by SK Chemicals Co., Ltd., H2 2016
  • Typhoid Fever - Pipeline by Zydus Cadila Healthcare Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Typhoid Fever - Dormant Projects, H2 2016
  • Typhoid Fever - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Typhoid Fever, H2 2016
  • Number of Products under Development for Typhoid Fever - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top